Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week

Aliment Pharmacol Ther. 1997 Jun;11(3):533-5. doi: 10.1046/j.1365-2036.1997.00166.x.

Abstract

Background: Furazolidone is an inexpensive antibiotic that has considerable anti-Helicobacter pylori activity in vitro.

Methods: Twenty-three patients with culture-proven H. pylori infection were treated for one week with a dual therapy containing omeprazole and furazolidone.

Results: Eradication succeeded in 10 of the first 20 evaluable patients (50%; 95% CI: 27.2-72.8%). This percentage was regarded as too low, and the study was terminated. Side-effects were mild.

Conclusion: With the possible increase in resistance to metronidazole and clarithromycin world-wide, furazolidone may be useful alternative in the treatment of H. pylori infection. Dual therapy for one week, however, is not sufficient.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Ulcer Agents / therapeutic use*
  • Drug Resistance, Microbial
  • Drug Therapy, Combination
  • Furazolidone / therapeutic use*
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Omeprazole / therapeutic use*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Furazolidone
  • Omeprazole